Scarica l'app Stockscreener
1.26
5.97%
-0.08
Dopo l'orario di chiusura:
1.27
0.01
+0.79%
Precedente Chiudi:
$1.34
Aprire:
$1.36
Volume 24 ore:
901.09K
Relative Volume:
3.70
Capitalizzazione di mercato:
$113.03M
Reddito:
-
Utile/perdita netta:
$-30.15M
Rapporto P/E:
-1.3846
EPS:
-0.91
Flusso di cassa netto:
$-31.63M
1 W Prestazione:
-10.00%
1M Prestazione:
+48.62%
6M Prestazione:
+45.65%
1 anno Prestazione:
-38.54%
Intervallo 1D:
$1.23
$1.4297
Intervallo di 1 settimana:
$1.23
$1.55
Portata 52W:
$0.49
$2.5899
Context Therapeutics Inc Stock (CNTX) Company Profile
Nome
Context Therapeutics Inc
Settore
Industria
Telefono
267-225-7416
Indirizzo
2001 MARKET STREET, PHILADELPHIA
Confronta CNTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
1.26 | 123.79M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Iniziato | Guggenheim | Buy |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2025-01-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-11-25 | Iniziato | D. Boral Capital | Buy |
| 2024-05-16 | Iniziato | Piper Sandler | Overweight |
Context Therapeutics Inc Borsa (CNTX) Ultime notizie
Is Context Therapeutics Inc. stock positioned well for digital economyWeekly Stock Recap & Target Return Focused Picks - newser.com
Is Context Therapeutics Inc a good long term investmentMonthly Performance Summary & Access Free Tools and Start Investing - earlytimes.in
Is Context Therapeutics Inc. stock in correction or buying zone2025 Big Picture & Weekly High Return Opportunities - newser.com
Is Context Therapeutics Inc. stock a defensive play in 2025July 2025 Review & Entry Point Confirmation Alerts - newser.com
Applying chart zones and confluence areas to Context Therapeutics Inc.2025 AllTime Highs & Technical Confirmation Alerts - newser.com
Does Context Therapeutics Inc. stock trade at a discount to peersEarnings Recap Summary & Real-Time Volume Analysis Alerts - newser.com
Can a trend reversal in Context Therapeutics Inc. lead to recoveryJuly 2025 Sentiment & Entry Point Confirmation Alerts - newser.com
Momentum divergence signals in Context Therapeutics Inc. chartGap Down & Stepwise Trade Signal Implementation - newser.com
How to use Fibonacci retracement on Context Therapeutics Inc.2025 Technical Overview & Expert Verified Stock Movement Alerts - newser.com
Context Therapeutics to Present New Data on Two Bispecific T Cell Engagers at SITC 2025 - MyChesCo
Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN
What drives Context Therapeutics Inc stock priceCandlestick Trading Patterns & Unlock Patterns Humans Can’t See - earlytimes.in
Is Context Therapeutics Inc. stock ready for a breakoutNew Guidance & Low Risk Entry Point Tips - newser.com
Will Context Therapeutics Inc. continue its uptrendLayoff News & AI Based Buy and Sell Signals - newser.com
Historical volatility pattern of Context Therapeutics Inc. visualizedQuarterly Earnings Summary & Community Supported Trade Ideas - newser.com
Real time social sentiment graph for Context Therapeutics Inc.Portfolio Update Summary & Free Weekly Watchlist of Top Performers - newser.com
Live market analysis of Context Therapeutics Inc.July 2025 Market Mood & Stepwise Swing Trade Plans - newser.com
Context Therapeutics Inc. stock momentum explained2025 Dividend Review & Risk Controlled Daily Trade Plans - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Context Therapeutics (NASDAQ:CNTX) - MarketBeat
How Context Therapeutics Inc. stock trades before earningsQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Is a relief rally coming for Context Therapeutics Inc. holdersIndex Update & AI Driven Stock Reports - newser.com
Is Context Therapeutics Inc. showing signs of accumulationEarnings Summary Report & Stepwise Trade Signal Implementation - newser.com
Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most - Yahoo Finance
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.20 Consensus PT from Analysts - Defense World
Context Therapeutics Grants Stock Options to New Hire - MSN
Will Context Therapeutics Inc. see short term momentumJuly 2025 Short Interest & Fast Moving Stock Watchlists - newser.com
Context Therapeutics Announces Poster Presentations at the - GlobeNewswire
Context Therapeutics Inc. to Present Trial Progress and Preclinical Data at SITC 2025 Annual Meeting - Quiver Quantitative
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of ... - Caledonian Record
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Stock Titan
Is it too late to sell Context Therapeutics Inc.2025 Winners & Losers & High Win Rate Trade Tips - newser.com
Context Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - MarketScreener
Developing predictive dashboards with Context Therapeutics Inc. dataJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Context Therapeutics announces inducement grant under Nasdaq listing rule - MarketScreener
GlobeNewswire by Notified - The Manila Times
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
30,000-Share Option: Context Therapeutics Grants New Hire Award at $0.97 Exercise Price, 10-year Term - Stock Titan
Context Therapeutics Gains 11%, Insider Trades Reap Benefit - simplywall.st
Context Therapeutics Inc Azioni (CNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Context Therapeutics Inc Azioni (CNTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Levit Alex C. | Chief Legal Officer, Corp. Sec |
Jun 06 '25 |
Buy |
0.58 |
20,000 |
11,520 |
29,000 |
| Minai-Azary Jennifer Lynn | Chief Financial Officer |
Jun 06 '25 |
Buy |
0.64 |
40,010 |
25,486 |
80,010 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):